Modelling the impact of ivermectin on River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho projections

Particle and Fibre Toxicology

María-Gloria Basáñez¹  Thomas S Churcher¹  Martin Walker¹  Hugo C Turner¹ 

[1] Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine (St. Mary’s Campus), Imperial College London, Norfolk Place, London W2 1PG, UK

关键词: Mortality;    Morbidity;    DALY;    Disease burden;    Mathematical modelling;    Ivermectin;    Control programmes;    Epidemiology;    Africa;    Onchocerciasis;    River blindness;    Neglected tropical diseases;   

Others  :  806286
DOI  :  10.1186/1756-3305-7-241

 received in 2014-05-13, accepted in 2014-05-19,  发布年份 2014

【 摘 要 】

Background

The African Programme for Onchocerciasis Control (APOC) has refocused its goals on the elimination of infection where possible, seemingly achievable by 15–17 years of annual mass distribution of ivermectin in some African foci. Previously, APOC had focused on the elimination of onchocerciasis as a public health problem. Timeframes have been set by the World Health Organization, the London Declaration on Neglected Tropical Diseases and the World Bank to achieve these goals by 2020–2025.

Methods

A novel mathematical model of the dynamics of onchocercal disease is presented which links documented associations between Onchocerca volvulus infection and the prevalence and incidence of morbidity and mortality to model outputs from our host age- and sex-structured onchocerciasis transmission framework (EpiOncho). The model is calibrated for African savannah settings, and used to assess the impact of long-term annual mass administration of ivermectin on infection and ocular and skin disease and to explore how this depends on epidemiological and programmatic variables.

Results

Current onchocerciasis disease projections, which do not account for excess mortality of sighted individuals with heavy microfilarial loads, underestimate disease burden. Long-term annual ivermectin treatment is highly effective at reducing both the morbidity and mortality associated with onchocerciasis, and this result is not greatly influenced by treatment coverage and compliance. By contrast, impact on microfilarial prevalence and intensity is highly dependent on baseline endemicity, treatment coverage and systematic non-compliance.

Conclusions

The goals of eliminating morbidity and infection with ivermectin alone are distinctly influenced by epidemiological and programmatic factors. Whilst the former goal is most certainly achievable, reaching the latter will strongly depend on initial endemicity (the higher the endemicity, the greater the magnitude of inter-treatment transmission), advising caution when generalising the applicability of successful elimination outcomes to other areas. The proportion of systematic non-compliers will become far more influential in terms of overall success in achieving elimination goals.

【 授权许可】

   
2014 Turner et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Duke BOL: Human onchocerciasis - an overview of the disease. Acta Leiden 1990, 59(1–2):9-24.
• [2]Plaisier AP, van Oortmarssen GJ, Remme JHF, Habbema JD: The reproductive lifespan of Onchocerca volvulus in West African savanna. Acta Trop 1991, 48(4):271-284.
• [3]Bradley JE, Whitworth J, Basáñez MG: Chapter 39: Onchocerciasis. In Topley and Wilson’s Microbiology and Microbial Infections. 10th edition. Edited by Wakelin D, Cox F, Despommier D, Gillespie S. London: Edward Arnold Publishers Ltd; 2005:781-801.
• [4]Hall LR, Pearlman E: Pathogenesis of onchocercal keratitis (River blindness). Clin Microbiol Rev 1999, 12(3):445-453.
• [5]Tamarozzi F, Halliday A, Gentil K, Hoerauf A, Pearlman E, Taylor MJ: Onchocerciasis: the role of Wolbachia bacterial endosymbionts in parasite biology, disease pathogenesis, and treatment. Clin Microbiol Rev 2011, 24(3):459-468.
• [6]Brattig NW: Pathogenesis and host responses in human onchocerciasis: impact of Onchocerca filariae and Wolbachia endobacteria. Microbes Infect 2004, 6(1):113-128.
• [7]Murdoch ME, Hay RJ, Mackenzie CD, Williams JF, Ghalib HW, Cousens S, Abiose A, Jones BR: A clinical classification and grading system of the cutaneous changes in onchocerciasis. Br J Dermatol 1993, 129(3):260-269.
• [8]Little MP, Breitling LP, Basáñez MG, Alley ES, Boatin BA: Association between microfilarial load and excess mortality in onchocerciasis: an epidemiological study. Lancet 2004, 363(9420):1514-1521.
• [9]Walker M, Little MP, Wagner KS, Soumbey-Alley EW, Boatin BA, Basáñez MG: Density-dependent mortality of the human host in onchocerciasis: relationships between microfilarial load and excess mortality. PLoS Negl Trop Dis 2012, 6(3):e1578.
• [10]Kirkwood B, Smith P, Marshall T, Prost A: Relationships between mortality, visual acuity and microfilarial load in the area of the Onchocerciasis Control Programme. Trans R Soc Trop Med Hyg 1983, 77(6):862-868.
• [11]Boatin BA, Richards FO Jr: Control of onchocerciasis. Adv Parasitol 2006, 61:349-394.
• [12]Basáñez MG, Pion SDS, Churcher TS, Breitling LP, Little MP, Boussinesq M: River Blindness: a success story under threat? PLoS Med 2006, 3(9):e371.
• [13]Duke BOL, Zea-Flores G, Munoz B: The embryogenesis of Onchocerca volvulus over the first year after a single dose of ivermectin. Trop Med Parasitol 1991, 42(3):175-180.
• [14]Basáñez MG, Pion SDS, Boakes E, Filipe JAN, Churcher TS, Boussinesq M: Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infect Dis 2008, 8(5):310-322.
• [15]Diawara L, Traoré MO, Badji A, Bissan Y, Doumbia K, Goita SF, Konaté L, Mounkoro K, Sarr MD, Seck AF, Toé L, Tourée S, Remme JHF: Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis 2009, 3(7):e497.
• [16]Traore MO, Sarr MD, Badji A, Bissan Y, Diawara L, Doumbia K, Goita SF, Konate L, Mounkoro K, Seck AF, Toé L, Tourée S, Remme JHF: Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. PLoS Negl Trop Dis 2012, 6(9):e1825.
• [17]Tekle A, Elhassan E, Isiyaku S, Amazigo U, Bush S, Noma M, Cousens S, Abiose A, Remme JHF: Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control. Parasit Vectors 2012, 5(1):28. BioMed Central Full Text
• [18]African Programme for Onchocerciasis Control: 18th Session of the Joint Action Forum. Bujumbura, Burundi; 2012. http://www.who.int/apoc/media/Journal_du_FAC_day_4_Anglais.pdf webcite
• [19]London Declaration on Neglected Tropical Diseases: Uniting to combat Neglected Tropical Diseases. Ending the neglect and reaching 2020 goals. London; 2012. http://unitingtocombatntds.org/downloads/press/ntd_event_london_declaration_on_ntds.pdf webcite
• [20]World Health Organization: Accelerating work to overcome the global impact of neglected tropical diseases– A roadmap for implementation. World Health Organization; 2012. http://www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf webcite
• [21]Basáñez MG, Boussinesq M: Population biology of human onchocerciasis. Philos Trans R Soc Lond B Biol Sci 1999, 354(1384):809-826.
• [22]Filipe JAN, Boussinesq M, Renz A, Collins RC, Vivas-Martinez S, Grillet ME, Little MP, Basáñez MG: Human infection patterns and heterogeneous exposure in river blindness. Proc Natl Acad Sci U S A 2005, 102(42):15265-15270.
• [23]Turner HC, Churcher TS, Walker M, Osei-Atweneboana MY, Prichard RK, Basáñez MG: Uncertainty surrounding projections of the long-term impact of ivermectin treatment for human onchocerciasis. PLoS Negl Trop Dis 2013, 7(4):e2169.
• [24]Churcher TS, Basáñez MG: Density dependence and the spread of anthelmintic resistance. Evolution 2008, 62(3):528-537.
• [25]Habbema D, Stolk W, Veerman L, de Vlas S: A rapid health impact assessment of APOC: exeutive summary & technical report. APOC; 2007. http://www.who.int/apoc/publications/APOC%20rapid%20HIA_final%20report_def.pdf webcite
• [26]Coffeng LE, Stolk WA, Zouré HGM, Veerman JL, Agblewonu KB, Murdoch ME, Noma M, Fobi G, Richardus JH, Bundy DAP, Habbema D, de Vlas SJ, Amazigo UV: African Programme for Onchocerciasis Control 1995–2015: model-estimated health impact and cost. PLoS Negl Trop Dis 2013, 7(1):e2032.
• [27]Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, Baxter A, Bell ML, Benjamin EJ, et al.: Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380(9859):2197-2223.
• [28]Winnen M, Plaisier AP, Alley ES, Nagelkerke NJ, van Oortmarssen G, Boatin BA, Habbema JD: Can ivermectin mass treatments eliminate onchocerciasis in Africa? Bull World Health Organ 2002, 80(5):384-391.
• [29]Plaisier AP, Alley ES, Boatin BA, Van Oortmarssen GJ, Remme JHF, De Vlas SJ, Bonneux L, Habbema JD: Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the Onchocerciasis Control Programme in West Africa. J Infect Dis 1995, 172(1):204-210.
• [30]Bottomley C, Isham V, Collins RC, Basáñez MG: Rates of microfilarial production by Onchocerca volvulus are not cumulatively reduced by multiple ivermectin treatments. Parasitology 2008, 135(13):1571-1581.
• [31]Pion SDS, Nana-Djeunga HC, Kamgno J, Tendongfor N, Wanji S, Njiokou F, Prichard RK, Boussinesq M: Dynamics of Onchocerca volvulus microfilarial densities after ivermectin treatment in an ivermectin-naïve and a multi-treated population from Cameroon. PLoS Negl Trop Dis 2013, 7(2):e2084.
• [32]Basáñez M-G, McCarthy JS, French MD, Yang G-J, Walker M, Gambhir M, Prichard RK, Churcher TS: A research agenda for helminth diseases of humans: modelling for control and elimination. PLoS Negl Trop Dis 2012, 6(4):e1548.
• [33]Anderson J, Fuglsang H, Hamilton PJS, De C, Marshall TF: Studies on onchocerciasis in the United Cameroon Republic II. Comparison of onchocerciasis in rain-forest and Sudan-savanna. Trans R Soc Trop Med Hyg 1974, 68(3):209-222.
• [34]Renz A, Fuglsang H, Anderson J: Studies on the dynamics of transmission of onchocerciasis in a Sudan-savanna area of North Cameroon IV. The different exposure to Simulium bites and transmission of boys and girls and men and women, and the resulting manifestations of onchocerciasis. Ann Trop Med Parasitol 1987, 81(3):253-262.
• [35]Prost A, Prod’hon J: Le diagnostique de l’onchocercose. Revue critique des méthodes en usage. Méd Trop Mars 1978, 38:519-532.
• [36]Coffeng LE, Pion SD, O’Hanlon S, Cousens S, Abiose AO, Fischer PU, Remme JHF, Dadzie KY, Murdoch ME, de Vlas SJ, Basáñez MG, Stolk WA, Boussinesq M: Onchocerciasis: the pre-control association between prevalence of palpable nodules and skin microfilariae. PLoS Negl Trop Dis 2013, 7(4):e2168.
• [37]Remme JHF, Ba O, Dadzie KY, Karam M: A force-of-infection model for onchocerciasis and its applications in the epidemiological evaluation of the Onchocerciasis Control Programme in the Volta River basin area. Bull World Health Organ 1986, 64(5):667-681.
• [38]Schulz-Key H, Kläger S, Awadzi K, Diallo S, Greene BM, Larivière M, Aziz MA: Treatment of human onchocerciasis: the efficacy of ivermectin on the parasite. Trop Med Parasitol (Suppl II) 1985, 36:20.
• [39]Albiez EJ, Walter G, Kaiser A, Ranque P, Newland HS, White AT, Greene BM, Taylor HR, Büttner DW: Histological examination of onchocercomata after therapy with ivermectin. Trop Med Int Health 1988, 39(2):93-99.
• [40]Cupp EW, Duke BOL, Mackenzie CD, Guzmán JR, Vieira JC, Mendez-Galvan J, Castro J, Richards FO, Sauerbrey M, Dominguez A, Eversole RR, Cupp MS: The effects of long-term community level treament with ivermectin (Mectizan) on adult Onchocerca volvulus in Latin America. Am J Trop Med Hyg 2004, 71(5):602-607.
• [41]Duke BOL: Evidence for macrofilaricidal activity of ivermectin against female Onchocerca volvulus: further analysis of a clinical trial in the Republic of Cameroon indicating two distinct killing mechanisms. Parasitology 2005, 130(4):447-453.
• [42]Whitworth JAG, Downham MD, Lahai G, Maude GH: A community trial of ivermectin for onchocerciasis in Sierra Leone: compliance and parasitological profiles after three and a half years of intervention. Trop Med Int Healt 1996, 1(1):52-58.
• [43]Gardon J, Boussinesq M, Kamgno J, Gardon-Wendel N, Demanga-Ngangue , Duke BOL: Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. Lancet 2002, 360(9328):203-210.
• [44]Collins RC, Gonzales-Peralta C, Castro J, Zea-Flores G, Cupp MS, Richards FO, Cupp EW: Ivermectin: reduction in prevalence and infection intensity of Onchocerca volvulus following biannual treatments in five Guatemalan communities. Am J Trop Med Hyg 1992, 47(2):156-169.
• [45]Alley ES, Plaisier AP, Boatin BA, Dadzie KY, Remme JHF, Zerbo G, Samba EM: The impact of five years of annual ivermectin treatment on skin microfilarial loads in the onchocerciasis focus of Asubende, Ghana. Trans R Soc Trop Med Hyg 1994, 88(5):581-584.
• [46]Little MP, Basáñez MG, Breitling LP, Boatin BA, Alley ES: Incidence of blindness during the Onchocerciasis control programme in western Africa, 1971–2002. J Infect Dis 2004, 189(10):1932-1941.
• [47]Remme JHF: Global burden of onchocerciasis in 1990. World Health Organization; 2004. http://www.who.int/healthinfo/global_burden_disease/Onchocerciasis%201990.pdf webcite
• [48]Shibuya K, Bernard C, Ezzati M, Mathers CD: Global burden of onchocerciasis in the year 2000: Summary of methods and data sources. World Health Organization; 2006. http://www.who.int/healthinfo/statistics/bod_onchocerciasis.pdf webcite
• [49]Ejere H, Schwartz E, Wormald R, Evans JR: Ivermectin for onchocercal eye disease (river blindness). Cochrane Database Syst Rev 2012., 8CD002219
• [50]Murdoch ME, Asuzu MC, Hagan M, Makunde WH, Ngoumou P, Ogbuagu KF, Okello D, Ozoh G, Remme JHF: Onchocerciasis: the clinical and epidemiological burden of skin disease in Africa. Ann Trop Med Parasitol 2002, 96(3):283-296.
• [51]Kipp W, Bamhuhiiga J: Onchodermal skin disease in a hyperendemic onchocerciasis focus in western Uganda. Am J Trop Med Hyg 2002, 67(5):475-479.
• [52]Ghalib HW, MacKenzie CD, Kron MA, Williams JF, el Khalifa M, el Sheikh H: Severe onchocercal dermatitis in the Ethiopian border region of Sudan. Ann Trop Med Parasitol 1987, 81(4):405-419.
• [53]Brieger WR, Awedoba AK, Eneanya CI, Hagan M, Ogbuagu KF, Okello DO, Ososanya OO, Ovuga EB, Noma M, Kale OO, Burnham GM, Remme JHF: The effects of ivermectin on onchocercal skin disease and severe itching: results of a multicentre trial. Trop Med Int Health 1998, 3(12):951-961.
• [54]Prost A: Latency period in onchocerciasis. Bull World Health Organ 1980, 58(6):923-925. In French
• [55]World Health Organization: Global Burden of Disease update 2004: disability weights for diseases and conditions. World Health Organization; 2004. http://www.who.int/healthinfo/global_burden_disease/GBD2004_DisabilityWeights.pdf webcite
• [56]World Health Organization: Making choices in health: WHO guide to cost-effectiveness analysis. World Health Organization; 2003. [http://www.who.int/choice/publications/p_2003_generalised_cea.pdf webcite]
• [57]African Programme for Onchocerciasis Control: Conceptual and operational framework of onchocerciasis elimination with ivermectin treatment. WHO/APOC; 2010. http://www.who.int/apoc/oncho_elimination_report_english.pdf webcite
• [58]Remme JHF, Dadzie KY, Rolland A, Thylefors B: Ocular onchocerciasis and intensity of infection in the community. I. West African savanna. Trop Med Parasitol 1989, 40(3):340-347.
• [59]Prost A, Prescott N: Cost-effectiveness of blindness prevention by the Onchocerciasis Control Programme in Upper Volta. Bull World Health Organ 1984, 62(5):795-802.
• [60]Hougard JM, Alley ES, Yaméogo L, Dadzie KY, Boatin BA: Eliminating onchocerciasis after 14 years of vector control: a proved strategy. J Infect Dis 2001, 184(4):497-503.
• [61]Duerr HP, Raddatz G, Eichner M: Control of onchocerciasis in Africa: threshold shifts, breakpoints and rules for elimination. Int J Parasitol 2011, 41(5):581-589.
• [62]Basáñez MG, Churcher TS, Grillet ME: Onchocerca-Simulium interactions and the population and evolutionary biology of Onchocerca volvulus. Adv Parasitol 2009, 68:263-313.
• [63]Borsboom GJJM, Boatin BA, Nagelkerke NJD, Agoua H, Akpoboua KLB, Alley EW, Bissan Y, Renz A, Yameogo L, Remme JHF, Habbema JD: Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West-Africa. Filaria J 2003, 2(1):8. BioMed Central Full Text
• [64]Katabarwa MN, Lakwo T, Habomugisha P, Agunyo S, Byamukama E, Oguttu D, Tukesiga E, Unoba D, Dramuke P, Onapa A, Tukahebwa EM, Lwamafa D, Walsh F, Unnasch TR: Transmission of Onchocerca volvulus continues in Nyagak-Bondo focus of northwestern Uganda after 18 years of a single dose of annual treatment with ivermectin. Am J Trop Med Hyg 2013, 89(2):293-300.
• [65]Katabarwa MN, Eyamba A, Nwane P, Enyong P, Yaya S, Baldiagai J, Madi TK, Yougouda A, Andze GO, Richards FO: Seventeen years of annual distribution of ivermectin has not interrupted onchocerciasis transmission in North Region. Cameroon Am J Trop Med Hyg 2011, 85(6):1041-1049.
• [66]Katabarwa MN, Eyamba A, Nwane P, Enyong P, Kamgno J, Kuete T, Yaya S, Aboutou R, Mukenge L, Kafando C, Siaka C, Mkpouwoueiko S, Ngangue D, Biholong BD, Andze GO: Fifteen years of annual mass treatment of onchocerciasis with ivermectin have not interrupted transmission in the West Region of Cameroon. J Parasitol Res 2013, 2013:420928.
• [67]Taylor MJ, Hoerauf A, Bockarie M: Lymphatic filariasis and onchocerciasis. Lancet 2010, 376(9747):1175-1185.
• [68]Thylefors B, Tonjum AM: A three-year follow-up of ocular onchocerciasis in an area of vector control. Bull World Health Organ 1980, 58(1):107-112.
• [69]Dadzie KY, Remme JHF, Rolland A, Thylefors B: The effect of 7–8 years of vector control on the evolution of ocular onchocerciasis in West African savanna. Trop Med Parasitol 1986, 37(3):263-270.
• [70]Emukah EC, Osuoha E, Miri ES, Onyenama J, Amazigo U, Obijuru C, Osuji N, Ekeanyanwu J, Amadiegwu S, Korve K, Richards FO: A longitudinal study of impact of repeated mass ivermectin treatment on clinical manifestations of onchocerciasis in Imo State. Nigeria Am J Trop Med Hyg 2004, 70(5):556-561.
• [71]Remme JHF, Feenstra P, Lever PR, Medici AC, Morel CM: Tropical diseases targeted for elimination: Chagas disease, lymphatic filariasis, onchocerciasis, and leprosy. In Disease Control Priorities in Developing Countries. Edited by Jamison DT, Breman JG, Measham AR. New York: Oxford University Press; 2006:433-449.
• [72]Ozoh GA, Murdoch ME, Bissek AC, Hagan M, Ogbuagu K, Shamad M, Braide EI, Boussinesq M, Noma MM, Murdoch IE, Sékétéli A, Amazigo UV: The African Programme for Onchocerciasis Control: impact on onchocercal skin disease. Trop Med Int Health 2011, 16(7):875-883.
• [73]Whitworth JA, Alexander ND, Seed P, Thomas W, Abiose A, Jones BR: Maintaining compliance to ivermectin in communities in two West African countries. Health Policy Plan 1996, 11(3):299-307.
• [74]Whitworth JA, Luty AJ, Maude GH, Morgan D, Downham MD, Taylor DW: Ivermectin does not reduce the burden of itching in an onchocerciasis endemic community. Trans R Soc Trop Med Hyg 1992, 86(3):281-283.
• [75]Somo RM, Ngosso A, Dinga JS, Enyong PA, Fobi G: A community-based trial of ivermectin for onchocerciasis control in the forest of southwestern Cameroon: clinical and parasitologic findings after three treatments. Am J Trop Med Hyg 1993, 48(1):9-13.
• [76]Whitworth JA, Maude GH, Downham MD: Clinical and parasitological responses after up to 6.5 years of ivermectin treatment for onchocerciasis. Trop Med Int Health 1996, 1(6):786-793.
• [77]Kennedy MH, Bertocchi I, Hopkins AD, Meredith SE: The effect of 5 years of annual treatment with ivermectin (Mectizan) on the prevalence and morbidity of onchocerciasis in the village of Gami in the Central African Republic. Ann Trop Med Parasitol 2002, 96(3):297-307.
• [78]Brieger WR, Okeibunor JC, Abiose AO, Wanji S, Elhassan E, Ndyomugyenyi R, Amazigo UV: Compliance with eight years of annual ivermectin treatment of onchocerciasis in Cameroon and Nigeria. Parasit Vectors 2011, 4:152. BioMed Central Full Text
• [79]Brieger WR, Okeibunor JC, Abiose AO, Ndyomugyenyi R, Wanji S, Elhassan E, Amazigo UV: Characteristics of persons who complied with and failed to comply with annual ivermectin treatment. Trop Med Int Health 2012, 17(7):920-930.
• [80]Duke BOL, Moore PJ, Anderson J: Studies on factors influencing the transmission of onchocerciasis. VII. A comparison of the Onchocerca volvulus transmission potentials of Simulium damnosum populations in four Cameroon rain-forest villages and the pattern of onchocerciasis associated therewith. Ann Trop Med Parasitol 1972, 66(2):219-234.
• [81]Dadzie KY, Remme JHF, Rolland A, Thylefors B: Ocular onchocerciasis and intensity of infection in the community. II. West African rainforest foci of the vector Simulium yahense. Trop Med Parasitol 1989, 40(3):348-354.
• [82]Cheke RA, Garms R: Indices of onchocerciasis transmission by different members of the Simulium damnosum complex conflict with the paradigm of forest and savanna parasite strains. Acta Trop 2013, 125(1):43-52.
• [83]Boussinesq M, Pion SDS, Demanga-Ngangue , Kamgno J: Relationship between onchocerciasis and epilepsy: a matched case–control study in the Mbam Valley, Republic of Cameroon. Trans R Soc Trop Med Hyg 2002, 96(5):537-541.
• [84]Pion SDS, Kaiser C, Boutros-Toni F, Cournil A, Taylor MM, Meredith SE, Stufe A, Bertocchi I, Kipp W, Preux PM, Boussinesq M: Epilepsy in onchocerciasis endemic areas: systematic review and meta-analysis of population-based surveys. PLoS Negl Trop Dis 2009, 3(6):e461.
• [85]Kipp W, Burnham G, Bamuhiiga J, Leichsenring M: The Nakalanga syndrome in Kabarole District, Western Uganda. Am J Trop Med Hyg 1996, 54(1):80-83.
• [86]Newell ED, Vyungimana F, Bradley JE: Epilepsy, retarded growth and onchocerciasis, in two areas of different endemicity of onchocerciasis in Burundi. Trans R Soc Trop Med Hyg 1997, 91(5):525-527.
• [87]Basáñez MG, French MD, Walker M, Churcher TS: Paradigm lost: how parasite control may alter pattern and process in human helminthiases. Trends Parasitol 2012, 28(4):161-171.
• [88]Zouré HGM, Wanji S, Noma M, Amazigo UV, Diggle PJ, Tekle AH, Remme JHF: The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS Negl Trop Dis 2011, 5(6):e1210.
• [89]Gardon J, Gardon-Wendel N, Demanga-Ngangue , Kamgno J, Chippaux JP, Boussinesq M: Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 1997, 350(9070):18-22.
• [90]Turner HC, Osei-Atweneboana MY, Walker M, Tettevi EJ, Churcher TS, Asiedu O, Biritwum N-K, Basáñez MG: The cost of annual versus biannual community-directed treatment with Ivermectin: Ghana as a case study. PLoS Negl Trop Dis 2013, 7(9):e2452.
• [91]Ndyomugyenyi R, Tukesiga E, Büttner DW, Garms R: The impact of ivermectin treatment alone and when in parallel with Simulium neavei elimination on onchocerciasis in Uganda. Trop Med Int Health 2004, 9(8):882-886.
• [92]Hoerauf A, Specht S, Büttner M, Pfarr K, Mand S, Fimmers R, Marfo-Debrekyei Y, Konadu P, Debrah AY, Bandi C, Brattig N, Albers A, Larbi J, Batsa L, Taylor MJ, Adjei O, Büttner DW: Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med Microbiol Immunol 2008, 197(3):295-311.